, IV, days 1 to 5 plus fluorouracil 450 mg=m 2 , IV, days 1 to 5, in a 3-weekly regimen). With the disease progression after 12 months, second-line chemotherapy was performed with doxorubicin (75 mg=m 2 , IV, day 1, a 3-weekly regimen, during seven cycles). In January 2007, oral capecitabine (1000 mg=m 2 , twice daily, on days 1 to 14) was started in a 3-weekly regimen because of bulky cervical, mediastinal, left axillary, diffuse lung nodules and dry cough, weight loss, watery diarrhea, and cervical pain. After four cycles of capecitabine, he showed remarkable symptomatic improvement with decreased diarrhea and pain, enhanced appetite, and lower carcinoembriogenic (CEA) level. He is now undergoing the eighth cycle of capecitabine with disease stabilization as shown by tumor diameters on clinical exams and chest radiograph, stable CEA level, better quality of life, and just one episode of grade-1 hand-foot syndrome.
Recently, Gilliam et al. (5) reported three patients diagnosed with metastatic MTC and treated with oral capecitabine, which is converted to the active metabolite 5-fluorouracil, preferentially in malignant tissues, by thymidylate phosphorylase. The authors found two patients with disease response and one of them with marked decrease in CEA level. These findings suggest that capecitabine is a reasonable option with clinical benefit, disease stabilization, and tolerable adverse effects. 
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